Company Encyclopedia
View More
name
BIODLINK-B
01875.HK
BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of newly diagnosed glioblastoma multiforme or anaplastic astrocytoma that recurs or progresses after conventional treatment. In addition, the company develops TAB014 that has completed Phase III clinical trial for the treatment of wet age-related macular degeneration (wAMD); TAE020, which is in preclinical trial to treat acute myeloid leukemia; and TAC020, which is in preclinical trial for the treatment of various solid tumors.
1.377 T
01875.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking11/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.00%D
    • Profit Margin0.68%C
    • Gross Margin72.18%A
  • Growth ScoreC
    • Revenue YoY9.79%B
    • Net Profit YoY-18.90%D
    • Total Assets YoY3.24%C
    • Net Assets YoY2.96%C
  • Cash ScoreA
    • Cash Flow Margin14695.12%A
    • OCF YoY9.79%B
  • Operating ScoreB
    • Turnover0.73B
  • Debt ScoreC
    • Gearing Ratio50.44%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MEIYOUHENG Wins NMPA Approval as World’s First EGFR-Targeting ADC from TOT BIOPHARM, BioDlink, and Lepu Biopharma

    TOT BIOPHARM, in collaboration with BioDlink and Lepu Biopharma, has received NMPA approval for MEIYOUHENG®, the first EGFR-targeting ADC drug. This marks a significant milestone as the first ADC fully manufactured by a CDMO to reach the Chinese market, showcasing advancements in the biopharmaceutical sector.

    Reuters·
    HK
    01875
    -0.58%
    Reuters·
    HK
    01875
    -0.58%

    In the first nine months, Dongyao Pharmaceutical reported a loss of 3.37 million RMB

    Dongyao Pharmaceutical - B announced that for the nine months ending in September, the operating revenue was 622 million RMB, a year-on-year decrease of 23%, mainly due to intensified market competition for self-developed products. It recorded a loss of 3.37 million RMB, compared to a net profit of 35.4 million RMB in the same period last year, turning from profit to loss

    AASTOCKS·
    HK
    01875
    -0.58%
    AASTOCKS·
    HK
    01875
    -0.58%

    BioDlink International Announces Board and Committee Restructuring

    BioDlink International Company Limited has announced a restructuring of its board and committees effective October 11, 2025. Mr. Fu Shan will chair the Strategy and ESG Committee, with Dr. Liu Weidong, Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin taking roles in various committees. This restructuring aims to improve governance and strategic oversight. The current analyst rating for TOT BIOPHARM International Co. Ltd. (HK:1875) is a Hold with a price target of HK$2.00.

    Tip Ranks·
    HK
    01875
    -0.58%
    Tip Ranks·
    HK
    01875
    -0.58%

    Dongyao Pharmaceutical-B: Fu Shan has been transferred from non-executive director to executive director

    Dongyao Pharmaceutical-B announced that Mr. Fu Shan will be transferred from non-executive director to executive director starting from October 11, 2025, responsible for leading the group's management and development. Dr. Liu Jun resigned from his positions as executive director and CEO for personal reasons, and Ms. Huang Chunying also resigned from her positions as non-executive director and vice chairman. Mr. Fu will succeed Dr. Liu as the company's authorized representative, with the appointment effective from October 11, 2025

    Zhitong·
    HK
    01875
    -0.58%
    Zhitong·
    HK
    01875
    -0.58%

    "Performance" Dongyao Pharmaceutical's interim net profit of 4.06 million RMB fell by 87% and no dividend is declared

    Dongyao Pharmaceutical - B announced its interim results for the six months ending in June, with revenue of 489 million RMB (the same below), a year-on-year decrease of 6%. It recorded a net profit of 4.06 million RMB, a decline of 87.1%, with earnings per share of 1 cent. No interim dividend is declared

    AASTOCKS·
    HK
    01875
    -0.58%
    AASTOCKS·
    HK
    01875
    -0.58%
    © 2025 Longbridge｜Disclaimer